Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy of Recombinant Epstein-Barr Virus (EBV) Vaccine in Patients With Nasopharyngeal Cancer Who Had Residual EBV DNA Load After Conventional Therapy

NCT01094405 is registered in ClinicalTrials.gov with Chinese University of Hong Kong as lead sponsor.

NCT NCT01094405
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01094405 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy of Recombinant Epstein-Barr Virus (EBV) Vaccine in Patients With Nasopharyngeal Cancer Who Had Residual EBV DNA Load After Conventional Therapy
Lead sponsor
Chinese University of Hong Kong
Phase
Phase 2
Overall status
Completed
Start date
March 31, 2010
Completion date
August 27, 2020
Enrollment
25 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

epstein-barr virus infections, nasopharyngeal cancer